The AI Revolution in Biotech: Recursion Pharmaceuticals Soars 19.18% on FDA’s New Approach to Animal Testing
In a move that has sent shockwaves through the biotechnology sector, the U.S. Food and Drug Administration (FDA) announced yesterday its plan to replace animal testing with “more effective, human-relevant methods,” including artificial intelligence (AI) models in drug development. And one stock is leading the charge: Recursion Pharmaceuticals Inc. (NASDAQ: RXRX). Shares of Recursion Pharmaceuticals … Read more